Petrichor

As we near the shortest day of the year, we're happy to share a long list of gratitude for tireless work, managing complex logistics, endless patience and smooth coordination. Thanks to the CLARA trial investigators and their amazing teams, their wonderful patients, and our own Aurionians for getting us to today's news! https://lnkd.in/g-SWTBxT

Today we announced the closing of our reverse merger with Pieris Pharmaceuticals. This milestone positions us strongly to enter the public markets with support from leading healthcare-dedicated investors to pursue our vision of becoming the leading rare disease company focused on developing and commercializing novel therapies for patients suffering from serious, rare genetic skin diseases. Trading begins December 16 on Nasdaq under ticker symbol PVLA. Learn more: http://bit.ly/3VEProC #raredisease #lymphaticmalformations

🌟 Exciting Leadership Development at Leukocare! 🌟 Leukocare AG is thrilled to announce the appointment of Cornelius Pompe as our new Chief Operating Officer (COO). With over 15 years of leadership experience in the biopharmaceutical sector, Cornelius brings a wealth of expertise in strategy, operations, and innovation. This strategic addition to our leadership team aligns perfectly with Leukocare's vision to transform biopharmaceutical stabilization and delivery solutions. Cornelius will play a pivotal role in driving operational excellence and strengthening our position as a global leader in our field. We're excited to embark on this journey together to shape the future of biopharma innovation. 🚀 https://lnkd.in/dxv8ibFr #Leadership #Biopharma #Innovation #Leukocare

With two years of reliable production of the medical isotope Lu-177 it was great for our entire partnership to come together and plan for the future and visit new facilities in Germany that will accept isotopes produced to and soon to be handled at Bruce Power for Global distribution. This is a first in the World and it’s thanks to strong team work between Gamzook’aamin aakoziwin (Saugeen Ojibway Nation Partnership), ITM Isotope Technologies Munich SE, Isogen (Kinectrics & Framatome) and Bruce Power. This builds off our announcement with Stephen Lecce and Lisa Thompson earlier this month. Our reliable supply of Lu-177 is used to treat Prostate Cancer and certain tumours and is also used in many clinical trials underway around the World. We look forward to building on this in support of Canadian Nuclear Isotope Council’s Isotopes for Hope Campaign to double production in Canada by 2030. This is a ‘Made in Ontario’ success story and an example of how our nuclear feel with stable energy policy from Ontario Government | Gouvernement de l’Ontario can create new platforms for innovation! Sam Oosterhoff Independent Electricity System Operator (IESO) Doug Ford Lisa Thompson Lesley Gallinger OMERS Infrastructure TC Energy Victor Fedeli Life Sciences Ontario

A very warm THANK YOU to all participants of the ICPO Theranostics Summit 2024 which took place last Nov 14 & 15, 2024 We are first and foremost grateful to all 35 speakers, moderators and panelists which made the ICPO Summit 2024 such a great success, allowing for over 400 attendees from all over the globe, including USA, China, Japan, Turkey, India, Egypt, Philippines, Mexico and Europe, to grow their knowledge and exchange with the community. If you did not attend and are keen to watch the ICPO Summit 2024 content, please send us an email at [email protected] before December 31, 2024. The talks will be available for three months from now. We are looking forward to welcoming you again for our next ICPO Summit edition in 2026! Stay tuned for the ICPO Forum 2025 on May 15 &16, 2025 in Munich. Check the website: www.icpo-forum.org Program of the ICPO Summit 2024: Day 1 - November 14 - Alpha Emitters with focus on Ac225, At211 and Pb212 - Latest innovation and clinical establishment today - Patient access and global perspective  Welcome Words  Keynote: History of Alpha Therapy  SESSION I: Alpha Emitters Fundamentals  SESSION II: Alpha Emitters from Bench to Bed Side  SESSION III: Alpha Emitters beyond PSMA  SESSION IV: Challenges of Alpha therapies versus conventional emitters  PANEL 1: Global perspective on patient access today and in 5 years Day 2 - November 15 - FAP Therapy Innovation and Clinical Profile - FAP in clinical trials – Patient Access and Global Perspective  Keynote: History of FAP till today  SESSION V: FAP Diagnostics in Oncology and non-Oncology  SESSION VI: FAP Therapy  PANEL 2: FAP as Imaging Biomarker  SESSION VII: CA9 and G250  SESSION VIII: CXCR4, GPC3 and GPC1  PANEL 3: Antibody Drug Conjugates contra Radiopharmaceutical Therapies?  FINAL ROUND TABLE: A new theranostics era for patients, fueled by innovation & regulatory advances  Wrap up and Closing of Summit 2024 Scientific Advisory Board of the ICPO Summit 2024: Univ.-Prof. Dr. Frederik Giesel, MD, MBA, Germany; Richard P. Baum, Germany; Cathy Cutler, USA; Ken Herrmann, Germany, Cristina Müller, Switzerland; Prof. Dr. Frank Rösch, Germany; Elcin Zan, MD Zan, USA Keynote speakers of the ICPO Theranostics Summit 2024: Steven Larson, Andrew Scott Speakers: Cathy Cutler, Pouget Lab (Jean-Pierre Pouget), Michael Nader, Mike Sathekge, Nick Pullen, Tadashi Watabe, Germo Gericke, Ebrahim Delpassand, M.D. , Neil Quigley, Jean-François GESTIN, Michael Schultz, Josh Mailman, Dr. Anna Karmann, Sherly Mosessian, sanjana ballal, Jacqueline Mock, Sze Ting Lee, Michael Hofman, David Cade, Rudolf Werner, Hakim Bouterfa, Wolfgang Weber, Pedro Fragoso Costa, Serada Satoshi ICPO Foundation-International Centers for Precision Oncology team: Odile Jaume, Martin Reuter, Marwa Hakkam, Karim Bouterfa, Andreas Noetzold, Susanne Simon, Katja Schorn #ICPOFoundation #Theranostics #Cancer #Cancercare #Oncology #NuclearMedicine #alphaemitters #radiopharmaceuticals #FAP

ICPO Foundation-International Centers for Precision Oncology partners with Munich Precision Oncology GmbH (MPO) to establish dedicated theranostics centers globally The Munich pilot center will serve as a functional demonstrator for ICPO. The Foundation will provide accreditation guidelines and certified training for improved patient outcomes. November 19, 2024 – Wiesbaden and Munich, Germany. The International Centers for Precision Oncology Foundation (ICPO) and Munich Precision Oncology GmbH (MPO) have announced a strategic partnership to establish a pilot center. This state-of-the-art facility in Garching, close to Munich, will leverage cutting-edge technology, and set new standards in radiomolecular cancer treatments. The center will be set up in collaboration between leading clinical, academic, and industrial partners. ICPO will provide practical training and certified education, as well as patient workflow guidelines and clinical protocols for innovative and effective patient outcomes through its international center accreditation model. The Munich pilot center will serve as a functional demonstrator for the ICPO Foundation and a benchmark for further centers globally. „This partnership, a pivotal step in our mission to scale and democratize access to precision oncology, is a testament to the expertise and reputation of the ICPO Foundation," said Odile JAUME, CEO ICPO Foundation. "The Munich pilot center by MPO will demonstrate the power of collaboration, elevate the significance of radiomolecular precision oncology, and ultimately transform patient care." Dr. Bent Reichardt, Managing Director of Munich Precision Oncology GmbH, shared similar enthusiasm: "We are excited to partner with ICPO in setting new standards in theranostics. Our aim is to establish the Munich pilot center as a model for patient-centered, state-of-the-art cancer treatment that integrates the latest innovation in imaging, analytics and treatment. It is our ambition to create both a lighthouse, as well as a replicable model that can be implemented in other regions, ultimately contributing to the advancement of global cancer care." Read the entire press release here: https://lnkd.in/eg-2edge For more information about Munich Precision Oncology: www.mp-onco.com ICPO team: Odile JAUME, Martin Reuter, Marwa Hakkam, Karim Bouterfa, Andreas Noetzold, Susanne Simon, Katja Schorn MPO team: Dr. Bent Reichardt; Oliver Buck; Paolina B. #ICPOFoundation #MunichPrecisionOncology #Theranostics #RadiomolecularPrecisionOncology #Cancer #Cancercare #Oncology #NuclearMedicine #Treatment #Cancertreatment #aAphaemitters #Radiopharmaceuticals #FAP #Radiopharmaceuticalstherapy #Therapy #Clinicaltrials #RLT #Ligands #Diagnostics #Alphatherapy 

💉 Are you working with high-concentration monoclonal antibodies? 🌟 Don't miss our on-demand webinar on cutting-edge SubQ formulations, featuring Dr. Karoline Bechtold-Peters from Novartis! In this must-see session, dive deep into the complexities of protein cluster formation and viscosity, driven by the interplay of short-range attraction and long-range repulsion. 🧬📊 👉 Watch now: https://lnkd.in/dZtjAMwW KEY TAKEAWAYS: 1️⃣ Patient-centric subcutaneous products are challenging due to the need for high antibody concentrations. 2️⃣ Protein cluster formation and viscosity depend on short-range attraction and long-range repulsion. 3️⃣ Volume limitations restrict protein concentration to 500 mg/mL; alternative techniques might be needed for higher doses. Gain valuable insights to tackle these challenges and drive innovation in your work! #MonoclonalAntibodies #Biotechnology #Pharmaceuticals #DrugDevelopment #SubQFormulations #ProteinScience #Webinar #Innovation #ScientificResearch #OnDemand

🚀 Unlocking New Horizons in Drug Formulation with Bioinformatics 🚀 At Leukocare AG, we’re redefining the future of drug product development through cutting-edge bioinformatics! Our approach goes beyond traditional methods, leveraging powerful AI-driven insights to streamline development, optimize formulations, and reduce costly lab time. 🧬 Why Bioinformatics? In the fast-paced world of biopharmaceuticals, every moment counts. Our advanced bioinformatics tools allow us to: Enhance drug stability and effectiveness through molecular modeling. Cut down on lab hours and resources with precise, data-driven design. Boost success rates by predicting the best formulation conditions from day one. 💡 Whether you’re in pre-clinical or clinical stages, our bioinformatics solutions are here to support every step of the way. Join us as we bring innovation to the forefront of drug formulation! 🔗 Discover more about how LEUKOCARE’s bioinformatics is transforming drug product development: https://lnkd.in/dZpixprv #Bioinformatics #DrugDevelopment #AI #Pharmaceuticals #Innovation

We continue growing and evolving. Today, we are thrilled to align with ABL to deepen our commitment to being an exceptional advanced #therapies #partner. The addition of the ABL Rockville team and facility aligns more than three decades of development and manufacturing experience with additional virus modalities and GMP capacity for adeno-associated virus (AAV) production. The merger also expands fill/finish capacity in the US making the combined group one of the few suppliers with a comprehensive R&D to commercial offering in the market. https://lnkd.in/eAYwrgds

Palvella’s recently awarded FDA Orphan Drug Grant to support the Phase 3 SELVA study evaluating QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations was featured in today’s FDA Law blog by James Valentine and Sarah Wicks from Hyman Phelps & McNamara. Palvella was awarded up to $2.6 million from the FDA’s Office of Orphan Products Development to support the SELVA study. www.fdalawblog.net #raredisease  #lymphaticmalformations